Document is current
Any future updates will be listed below
-
Authors
Uchihashi, Yosuke
Noda, Tatsuya
Inagaki, Yusuke
Ogiwara, Kenichi
Mawarikado, Yuya
Nishioka, Yuichi
Myojin, Tomoya
Amano, Kagehiro
Shirahata, Akira
Nogami, Keiji
Kido, Akira
Imamura, Tomoaki
-
Funding
Funding for this research was provided by:
The Ministry of Health, Labour and Welfare, Japan (20HB1001, 20HB1001, 20HB1001, 20HB1001, 20HB1001, 20HB1001, 20HB1001, 20HB1001, 20HB1001)
Japan Society for the Promotion of Science (JP20H00623, JP20H00623, JP20H00623)
- License Information
-
More Information
Article History
Received: 18 January 2025
Accepted: 10 April 2025
First Online: 16 April 2025
Declarations
:
: This study was approved by the ethics committee of Nara Medical University (project approval number: 2831) and was conducted in accordance with the tenets of the Declaration of Helsinki and its later amendments. Individually identifiable data were removed from the claims database and were not provided to the researcher. The requirement for informed consent was waived due to the law in Japan.
: Not applicable.
: YI has received specified clinical trial funding from MediaMart Co., Ltd.; research funding from Chugai Pharmaceutical Co., Ltd., Johnson & Johnson K.K., KM Biologics, Olympus Terumo Biomaterials Corp., and Zimmer Biomet; and honoraria from Asahi Kasei Pharma Corporation, Bayer Yakuhin Ltd., Chugai Pharmaceutical Co., Ltd., CSL Behring, Healious K.K., Hisamitsu Pharmaceutical Co., Johnson & Johnson K.K., Ono Pharmaceutical Co., Ltd., Novo Nordisk Pharma Ltd., Sanofi K.K., and Takeda Pharmaceutical Co., Ltd.; and is a medical advisor for Chugai Pharmaceutical Co., Ltd. and KM Biologics.KO has received personal fees from Chugai Pharmaceutical Co., Ltd., and CSL Behring.YM is a member of Medicinal Biology of Thrombosis and Hemostasis established by Nara Medical University and Chugai Pharmaceutical Co., Ltd.YN has received personal fees from Sanofi, Daiichi Sankyo Company, Limited, and DeSC Healthcare.TM has received personal fees from Health Insurance Claims Review & Reimbursement services.KA has received consulting fees from Chugai Pharmaceutical Co., Ltd.; speakers’ fees from Bayer, Chugai Pharmaceutical Co., Ltd., CSL Behring, Japan Blood Products Organization, KM Biologics, Novo Nordisk, Pfizer, Sanofi, Fujimoto Pharmaceutical Corporation and Takeda; research funding from KM Biologics Co., Ltd.; and is an entity’s board of directors or advisory committee member for Chugai Pharmaceutical Co., Ltd.AS has received consulting fees from KM Biologics Co., Ltd., and speakers’ fees from CSL Behring, Sanofi, Pfizer, and Takeda Co., Ltd.KN has received grants, personal fees, and nonfinancial support from Chugai Pharmaceutical Co., Ltd.; personal fees from Hoffmann-La Roche, Ltd.; grants and personal fees from Sysmex Co., Sekisui Medical. Co., Ltd., Takeda Pharmaceutical Co., Ltd., Sanofi S.A. Co., Ltd., CSL Behring Co., KM Biologics Co., Ltd., Novo Nordisk A/S, Bayer AG, and Fujimoto Seiyaku; is an inventor of patents relating to emicizumab; and is a member of Medicinal Biology of Thrombosis and Hemostasis established by Nara Medical University and Chugai Pharmaceutical Co., Ltd.YU, TN, AK and TI have no conflicts of interest to report.
